Products

SH-111

A treatment for T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL )

Disease State Overview

  • There are approximately 5,690 patients in the US diagnosed with Acute Lymphoblastic Leukemia (ALL) per year1
  • It is estimated that 10-15% of these ALL patients have T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL )1
  • The majority of these patients are children under 5 years of age.

Regulatory Status

Shorla Oncology have submitted, and the US Food and Drug Administration (‘FDA’) have accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia. SH-111 is a life changing treatment that is often in shortage and the company looks forward to working closely with FDA to bring this much needed product to market in 2022.

Read more at: https://www.businesswire.com/news/home/20210423005122/en/Shorla-Pharma-Announces-FDA-Filing-Acceptance-and-Priority-Review-for-T-cell-Leukemia-Treatment

1 American Cancer Society. Cancer Facts & Figures, 2021.